Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Efficacy and Safety in Generalized Anxiety Disorder
NCT00744627Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of vortioxetine in generalized anxiety disorder (GAD), sponsored by Takeda. Started Sep 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00744627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00744627.